BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Numerous studies have demonstrated the persistence of CML leukemic cells in the BM niche following treatment, even in patients with undetectable levels of the BCR-ABL1 transcript, proving that the standardized MRD monitoring system is not always effective [32, 93].